Skip to content

the effect of lacto ovo vegetarian and normal diets in nonalcoholic fatty liver disease

Comparing the therapeutic effects of lacto-Ovo-vegetarian and standard diet on the lipid profile, liver enzymes, and sonographic results of obese and overweight patients with nonalcoholic fatty liver disease: A randomized controlled trial.

Status
Active, not recruiting
Phases
Phase 3
Study type
Interventional
Source
IRCT
Registry ID
IRCT20140208016529N2
Enrollment
80
Registered
2018-05-31
Start date
2017-12-30
Completion date
Unknown
Last updated
2020-08-17

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Nonalcoholic Fatty Liver Disease.. Nonalcoholic steatohepatitis (NASH)

Interventions

Intervention 1: The energy requirements of intervention group are calculated with Mifflin-St Jeor equation on the basis of weight, height, age, and sex of each participant. Take into account the patie

Sponsors

Vice Chancellor for Research, Isfahan University of Medical Sciences
Lead Sponsor

Eligibility

Sex/Gender
All
Age
20 Years to 55 Years

Inclusion criteria

Inclusion criteria: Over-weight or obese patients with the nonalcoholic fatty liver disease confirmed with imaging techniques increased levels of liver enzymes (serum levels of alanine aminotransferase and aspartate aminotransferase more than 40 U/L); Body Mass Index (BMI) of them is greater than 24.9 and lower than 40

Exclusion criteria

Exclusion criteria: Alcohol consumption Pregnant and lactating women Any known forms of hepatic or metabolic disease except NAFLD, such as hereditary hemochromatosis, Wilson’s disease, cirosis, other metabolic disease history of gastric bypass or intestine surgery Taking hepatotoxic drugs such as calcium channel blocker, methotrexate, amiodarone, chloroquine and anti inflammatory drugs; Using nutrition supplements or vegetarian diets Hormone Therapy Patients with a history of hypothyroidism, Cushing’s syndrome renal failure kidney stones. Participants with less than 80% of adherence to the dietary plan are going to be excluded.

Design outcomes

Primary

MeasureTime frame
Liver enzymes (ALT, AST, ALP). Timepoint: The first day of the study and the last day of 12th week. Method of measurement: Using Microgram/ml - laboratory kit.;Lipid profile (TG, LDL, HDL, Total cholestrol). Timepoint: The first day of the study and the last day of 12th week. Method of measurement: laboratory kit.;Liver steatosis index. Timepoint: The first day of the study and the last day of 12th week. Method of measurement: Sonography.

Secondary

MeasureTime frame
Waist to hip ratio. Timepoint: The first day of the study and the last day of 12th week. Method of measurement: Non-stretchable tape without any pressure.;Body Mass Index (BMI). Timepoint: The first day of the study and the last day of 12th week. Method of measurement: Weight (kilograms) divided by the square of height (meters).;Sistolic and diastolic blood pressure. Timepoint: The first day of the study and the last day of 12th week. Method of measurement: By mercury sphygmomanometer.

Countries

Iran (Islamic Republic of)

Contacts

Public ContactNazila Garousi

Esfahan University of Medical Sciences

Garousinazila@yahoo.com+98 31 3668 8487

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026